4//SEC Filing
KALOBIOS PHARMACEUTICALS INC 4
Accession 0001144204-15-066696
CIK 0001293310operating
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 4:08 PM ET
Size
11.4 KB
Accession
0001144204-15-066696
Insider Transaction Report
Form 4
Shkreli Martin
10% Owner
Transactions
- Purchase
Common Stock
2015-11-16$0.61/sh+500,169$305,103→ 914,254 total - Purchase
Common Stock
2015-11-16$1.43/sh+97,269$139,095→ 1,011,523 total - Purchase
Common Stock
2015-11-17$2.43/sh+7,000$17,010→ 1,625,200 total - Purchase
Common Stock
2015-11-17$1.93/sh+606,677$1,170,887→ 1,618,200 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 500,169 shares in multiple transactions at prices ranging from $0.3 to $.79, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- [F2]The securities reported herein are owned directly by Martin Shkreli, who is a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. There is no voting or ownership agreement amongst the group members and the other members of the group do not have a pecuniary interest in the shares reported herein. Correspondingly, Mr. Shkreli does not have a pecuniary interest in the shares owned by the other members of the group.
- [F3]The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 606,677 shares in multiple transactions at prices ranging from $1.38 to $2.37, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. Martin Shkreli purchased 7,000 shares in multiple transactions at prices ranging from $2.38 to $2.45, inclusive. The reporting person undertakes to provide to Kalobios Pharmaceuticals, Inc., any security holder of Kalobios Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
Documents
Issuer
KALOBIOS PHARMACEUTICALS INC
CIK 0001293310
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001293310
Filing Metadata
- Form type
- 4
- Filed
- Nov 17, 7:00 PM ET
- Accepted
- Nov 18, 4:08 PM ET
- Size
- 11.4 KB